Commercializing an orphan drug can be challenging, however, using a framework and a checklist that incorporates the right elements can prove beneficial.
Nitin Riyal
Advertisement
Director, Axtria
Articles by Nitin Riyal
Advertisement
Latest Updated Articles
Developing a Product Launch Strategy for an Orphan DrugSeptember 14th 2021
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909
2
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
3
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
4
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
5